Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. (17th November 2018)

• Record Type: Journal Article
• Authors: Ganassin, Rayane; Merker, Carolin; Rodrigues, Mosar Corrêa; Guimarães, Nayara Felipe; Sodré, Carine Sampaio Cerqueira; Ferreira, Queila da Silva; da Silva, Sebastião William; Ombredane, Alicia Simalie; Joanitti, Graziella Anselmo; Py-Daniel, Karen Rapp; Zhang, Juan; Jiang, Cheng-Shi; de Morais, Paulo César; Mosiniewicz-Szablewska, Ewa; Suchocki, Piotr; Longo, João Paulo Figueiró; Meijer, Jan; Estrela-Lopis, Irina; de Azevedo, Ricardo Bentes; Muehlmann, Luis Alexandre
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46:Number 8(2018)
• Page Start: 2002
• Page End: 2012
• Publication Date: 2018-11-17
• Subjects: Nanotechnology -- drug delivery systems -- nanostructures -- cardiotoxicity -- cancer; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2017.1408020
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Nanocapsules (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed. These nanocapsules are spherical, with an average hydrodynamic diameter of about 170 nm, and with negative zeta potential. NCS-DOX effectively co-delivered the selol and the doxorubicin into 4T1 cells and changed the intracellular distribution of DOX from the nuclei to the mitochondria. Moreover, a significantly increased cytotoxicity against 4T1 cells was observed, which is suggestive of additive or synergic effect of selol and doxorubicin. In conclusion, PVM/MA nanocapsules are suitable platforms to co-deliver drugs into cancer cells.